The CDK4 and 6 inhibitor abemaciclib induces both epigenetic and immunogenic responses in preclinical models of Ewing's sarcoma

被引：0
|
作者：
Dowless, Michele [1 ]
Lowery, Caitlin [1 ]
Renschler, Matthew [1 ]
Blosser, Wayne [1 ]
Stephens, Jennifer [1 ]
Flack, Robert [1 ]
Credille, Kelly [1 ]
Chen, Mia [1 ]
Dorsey, Frank [1 ]
Sams, Lillian [1 ]
Ebert, Philip [1 ]
Olsen, Jonathan [1 ]
Shackleford, Terry [2 ]
Houghton, Peter [2 ]
Stancato, Louis [1 ]
机构：
[1] Eli Lilly & Co, Indianapolis, IN 46285 USA
[2] UT Hlth Sci Ctr, Greehey Childrens Canc Res Inst, San Antonio, TX USA
来源：
CANCER RESEARCH | 2018年 / 78卷 / 19期
关键词：
D O I：
10.1158/1538-7445.PEDCA17-B43
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
B43
引用
收藏
页数：2
相关论文
共 50 条
  • [21] THE CDK4/6 INHIBITOR ABEMACICLIB IN PATIENTS WITH RECURRENT MENINGIOMA AND OTHER PRIMARY CNS TUMORS
    Coffee, Elizabeth
    Panageas, Katherine
    Young, Robert
    Morrison, Tara
    Daher, Ahmad
    Grommes, Christian
    Gavrilovic, Igor T.
    Lin, Andrew
    Miller, Alexandra
    Schaff, Lauren
    Daras, Mariza
    DeAngelis, Lisa
    Diamond, Eli
    Piotrowski, Anna
    Malani, Rachna
    Nolan, Craig
    Pentsova, Elena
    Santomasso, Bianca
    Stone, Jacqueline
    Nair, Suresh
    Mellinghoff, Ingo K.
    Kaley, Thomas
    NEURO-ONCOLOGY, 2021, 23 : 72 - 73
  • [22] Abemaciclib, a CDK4/6 inhibitor, exerts preclinical activity against aggressive germinal center derived B-cell lymphomas
    Tanaka, Yuka
    Momose, Shuji
    Tabayashi, Takayuki
    Tokihira, Michihide
    Tamaru, Jun-ichi
    Kizaki, Masahiro
    CANCER SCIENCE, 2021, 112 : 547 - 547
  • [23] Preclinical evaluation of CDK4/6 inhibitor and biomarker exploration in gastric cancer
    Bae, Hyun Joo
    Kwon, Woo Sun
    Kim, Hyun Jeong
    Kang, Sun Kyoung
    Jeong, Inhye
    Kim, Tae Soo
    Chung, Hyun Cheol
    Rha, Sun Young
    CANCER RESEARCH, 2018, 78 (13)
  • [24] Trilaciclib, a CDK4/6 inhibitor, does not impair the efficacy of chemotherapy in CDK4/6-dependent tumor models
    Sorrentino, J.
    Bisi, J.
    Thompson, D.
    Lai, A.
    Strum, J.
    Roberts, P.
    EUROPEAN JOURNAL OF CANCER, 2018, 103 : E47 - E48
  • [25] The CDK4/6 inhibitor abemaciclib induces synergistic immune activation and antitumor efficacy in combination with PD-L1 blockade
    Dempsey, Jack
    Huber, Lysiane
    Forest, Amelie
    Stephens, Jennifer R.
    Doman, Thompson N.
    Manro, Jason
    Capen, Andrew
    Flack, Robert S.
    Donoho, Gregory P.
    Buchanan, Sean
    De Dios, Alfonso
    Driscoll, Kyla
    Kalos, Michael
    Novosiadly, Ruslan
    Beckmann, Richard P.
    Schaer, David A.
    CANCER RESEARCH, 2017, 77
  • [26] Abemaciclib, a CDK4/6 inhibitor, exerts preclinical activity against aggressive germinal center-derived B-cell lymphomas
    Tanaka, Yuka
    Momose, Shuji
    Tabayashi, Takayuki
    Sawada, Keisuke
    Yamashita, Takahisa
    Higashi, Morihiro
    Sagawa, Morihiko
    Tokuhira, Michihide
    Rosenwald, Andreas
    Kizaki, Masahiro
    Tamaru, Jun-ichi
    CANCER SCIENCE, 2020, 111 (02) : 749 - 759
  • [27] CDK4/6 dual inhibitor abemaciclib demonstrates compelling preclinical activity against esophageal adenocarcinoma: a novel therapeutic option for a deadly disease
    Kosovec, Juliann E.
    Zaidi, Ali H.
    Omstead, Ashten N.
    Matsui, Daisuke
    Biedka, Mark J.
    Cox, Erin J.
    Campbell, Patrick T.
    Biederman, Robert W. W.
    Kelly, Ronan J.
    Jobe, Blair A.
    ONCOTARGET, 2017, 8 (59) : 100421 - 100432
  • [28] An UHPLC-MS/MS method for quantification of the CDK4/6 inhibitor abemaciclib in human serum
    Habler, Katharina
    Vogeser, Michael
    Teupser, Daniel
    JOURNAL OF MASS SPECTROMETRY AND ADVANCES IN THE CLINICAL LAB, 2022, 24 : 15 - 21
  • [29] Efficacy of CDK4/6 inhibitors in preclinical models of malignant pleural mesothelioma
    Elisabet Aliagas
    Ania Alay
    Maria Martínez-Iniesta
    Miguel Hernández-Madrigal
    David Cordero
    Mireia Gausachs
    Eva Pros
    Maria Saigí
    Sara Busacca
    Annabel J. Sharkley
    Alan Dawson
    Ramón Palmero
    José C. Ruffinelli
    Susana Padrones
    Samantha Aso
    Ignacio Escobar
    Ricard Ramos
    Roger Llatjós
    August Vidal
    Eduard Dorca
    Mar Varela
    Montse Sánchez-Céspedes
    Dean Fennell
    Cristina Muñoz-Pinedo
    Alberto Villanueva
    Xavi Solé
    Ernest Nadal
    British Journal of Cancer, 2021, 125 : 1365 - 1376
  • [30] FDA approves Novartis's CDK4/6 inhibitor
    Mullard A.
    Nature Reviews Drug Discovery, 2017, 16 (4) : 229 - 229
12345